MethylGene Inc.
epigenetic biomarkers and therapeutics targeting methylation-based disease mechanisms
- Sector
- Biotech
- Headquarters
- MONTREAL, A8
- Latest Form D
- $26.1M, Nov 2012
- Total capital
- $61.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $61.6M
- 2 Form D · last Nov 2012
- 167 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 21 pending · first 2013
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$26.1M
- Private capital raisedForm D · SEC · 1st filing$35.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- ANDRE ARCHIMBAUDDirectorNamed in SEC Form D filings
- ARKADII B. VAISBURGExecutive OfficerNamed in SEC Form D filings
- ARKADIL B. VAISBURGExecutive OfficerNamed in SEC Form D filings
- CHARLES W. BAUMExecutive Officer, DirectorNamed in SEC Form D filings
- CHARLES R. GRUBSZTAJNExecutive Officer, DirectorNamed in SEC Form D filings
- COLIN R. MALLETDirectorNamed in SEC Form D filings
Show all 19 people
- DAVID J. DRUTZDirectorNamed in SEC Form D filings
- GREGORY B. REIDExecutive OfficerNamed in SEC Form D filings
- HENRY J. FUCHSDirectorNamed in SEC Form D filings
- JAY R. MOORINDirectorNamed in SEC Form D filings
- JEFFREY M. BESTERMANExecutive OfficerNamed in SEC Form D filings
- JOSEPH B. WALEWICZExecutive OfficerNamed in SEC Form D filings
- KLAUS B. KEPPERExecutive OfficerNamed in SEC Form D filings
- LOUIS W. LACASSEDirectorNamed in SEC Form D filings
- MARTIN GODBOUTExecutive Officer, DirectorNamed in SEC Form D filings
- PEGGY R. MULLIGANDirectorNamed in SEC Form D filings
- PETER W. THOMPSONDirectorNamed in SEC Form D filings
- RACHEL B. HUMPHREYExecutive OfficerNamed in SEC Form D filings
- RODNEY W. LAPPEDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 26- GrantedProdrugs Of Compounds That Enhance Antifungal Activity And Compositions Of Said ProdrugsUSPTOUS 9,636,298
- PendingDibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC InhibitorsUSPTOApplication 14853222
- GrantedDibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC InhibitorsUSPTOUS 9,193,749
Show all 26 patent records
- Prodrugs Of Compounds That Enhance Antifungal Activity And Compositions Of Said ProdrugsMay 2, 2017 · US 9,636,298Granted
- Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC InhibitorsAug 4, 2016 · Application 14853222Pending
- Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC InhibitorsNov 24, 2015 · US 9,193,749Granted
- Processes and Intermediates for Preparing Fused Heterocyclic Kinase InhibitorsApr 28, 2015 · US 9,018,378Granted
- Methods Of Treatment Of Cell Proliferative And/or Ophthalmic Diseases, Disorders And Conditions Using Inhibitors Of Protein Tyrosine Kinase ActivityOct 23, 2014 · Application 14308408Pending
- Inhibitors Of Protein Tyrosine Kinase ActivitySep 30, 2014 · US 8,846,927Granted
- Methods Of Inhibiting Protein Tyrosine Kinase ActivityJun 26, 2014 · Application 14194155Pending
- Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal AgentsMar 20, 2014 · Application 13827708Pending
- Inhibitors Of Histone DeacetylaseFeb 13, 2014 · Application 13829403Pending
- Inhibitors Of Histone Deacetylase And Prodrugs ThereofJan 23, 2014 · Application 13829095Pending
- Inhibitors Of Histone DeacetylaseDec 3, 2013 · US 8,598,168Granted
- Selected Inhibitors of Protein Tyrosine Kinase ActivityApr 18, 2013 · Application 13628975Pending
- Inhibitors of Protein Tyrosine Kinase ActivityApr 18, 2013 · Application 13629019Pending
- Inhibitors of Protein Tyrosine Kinase ActivityApr 18, 2013 · Application 13629050Pending
- Inhibitors of Protein Tyrosine Kinase ActivityApr 11, 2013 · Application 13629072Pending
- Inhibitors Of Histone DeacetylaseApplication PCTUS2009042869Pending
- Methods For Treating Cognitive Disorders Using Inhibitors Of Histone DeacetylaseApplication PCTUS2009042818Pending
- Potentiation Of Antifungal CompoundsApplication PCTUS2007075563Pending
- Novel Sulfonamidomethylphosphonate Inhibitors Of Beta-lactamaseApplication PCTUS2007011977Pending
- Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said ProdrugsApplication 61928978Pending
- Inhibitors Of Histone DeacetylaseApplication PCTUS2007066045Pending
- Inhibitors Of Dna MethyltransferaseApplication PCTUS2006001791Pending
- Inhibitors Of Histone DeacetylaseApplication PCTUS2004031590Pending
- Inhibitors Of Histone DeacetylaseApplication PCTUS2004031591Pending
- Novel Inhibitors Of B-lactamaseApplication PCTUS2003036929Pending
- Inhibitors Of Histone DeacetylaseApplication PCTUS2002029017Pending
Related companies, and why
- BRITEBIO, INC.Similar federal contract value in Biotech · null in contracts
- LumaCyte, Inc.Similar federal contract value in Biotech · null in contracts
- Surface Ophthalmics, Inc.Similar federal contract value in Biotech · null in contracts
- OtonomySimilar federal contract value in Biotech · null in contracts
- Endlyz Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Avilar TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .